RJ Health - Pipeline Drugs with Associated Genetic Tests - Webinar Segment скачать в хорошем качестве

RJ Health - Pipeline Drugs with Associated Genetic Tests - Webinar Segment

This segment is from RJ Health's Webinar: "Precision Medicine for Health Plans" In collaboration with Concert Genetics and Burgess. View the full webinar here: http://www2.rjhealthsystems.com/WB-On... [Todd Cooperman] Now, the other piece is, okay, great, so we have these 27 products, pretty small compared to the hundreds or thousands of products that we're dealing with today from a cost perspective, not a big issue. Well, my team and I conducted an analysis looking at the pipeline, and we looked at everything from Phase I to even Phase IV, so post-marketing clinical studies that are currently in process. There were over 4,300 of those studies. And then what we did is we actually looked at what was exactly being studied for each one of those specific clinical studies, and whether the specific study had the intent of looking for specific genetic markers, making an assumption, whether it's correct or not, that the reason they're studying to determine whether that genetic marker is a useful indicator for the treatment of a specific disease state, that their intent is to go pursue some type of a genetic test marker when they're finally applied to market. So, we basically classified these into three different groups, if you're looking at this. So, there's the orange, which is based on what we found, is that genetic test is quite possible for that specific usage. There is a subset where we were unable to determine, based off the information for the clinical trial whether that was their intent or not, and then there were some that were straightforward, they're not even close, there's nothing in here to suggest that it's a genetic test. But overall what we found is that 34%, about 1,400 of those clinical studies were tied to some type of a genetic marker. And as you can see, if you look at Phase IV, which is about 146 clinical trials, so those are currently marketed drugs, but then if you look at Phase III, that number is increased to 184, and then Phase II, granted a lot of those trials will fail, there is 467. So, there is definitely, there is a robust pipeline in process for drugs that are in cryogenic testing, suggesting that we really need to think about this now, because that number is going to increase over time.